Delving into the Latest Updates on SCT-C21 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

SCTC21, SCTC21C

Target

CD38

Action

inhibitors

Mechanism

CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors)

Therapeutic Areas

Immune System DiseasesUrogenital DiseasesNeoplasms+ [3]

Active Indication

Multiple MyelomaImmunoglobulin Light-Chain AmyloidosisGlomerulonephritis, IGA+ [2]

Inactive Indication-

Originator Organization

Sinocelltech Group Ltd.

Active Organization

Shenzhou Cell Engineering Co. Ltd.

Sinocelltech Group Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Start Date29 Dec 2025

Sponsor / Collaborator

Sinocelltech Group Ltd.

NCT06774664

/ Not yet recruitingPhase 1/2

A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases

Start Date01 Jan 2025

Sponsor / Collaborator

Sinocelltech Group Ltd.

NCT06252298

/ RecruitingPhase 1

A Phase I Clinical Study Evaluating the Safety and Efficacy of SCTC21C in Participants With CD38+ Hematologic Malignancies

The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies

Start Date28 Feb 2024

Sponsor / Collaborator

Sinocelltech Group Ltd.

100 Clinical Results associated with SCT-C21

Login to view more data

100 Translational Medicine associated with SCT-C21

Login to view more data

100 Patents (Medical) associated with SCT-C21

Login to view more data

100 Deals associated with SCT-C21

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 3	China	Sinocelltech Group Ltd.	29 Dec 2025
Immunoglobulin Light-Chain Amyloidosis	Phase 3	China	Shenzhou Cell Engineering Co. Ltd.	12 Dec 2025
Glomerulonephritis, IGA	Phase 2	China	Sinocelltech Group Ltd.	01 Jan 2025
CD38-Positive Hematologic Neoplasms	Phase 1	China	Sinocelltech Group Ltd.	28 Feb 2024
Hematologic Neoplasms	IND Approval	China	Shenzhou Cell Engineering Co. Ltd.	18 Jan 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data